Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + rituximab induction followed by rituximab maintenance in elderly untreated follicular lymphoma
2010-020757-14Phase 2Completed
- Sponsor
- LYSARC
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and rituximab in follicular lymphoma (FL), sponsored by LYSARC. Primary endpoints: Response rate after short treatment with rituximab and bendamustine and Complete response rate according to Cheson 1999. Started Feb 2011; status: completed.
02
Drugs
bendamustinerituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2010-020757-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020757-14.